Literature DB >> 7882559

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

A M Jackson1, A B Alexandroff, R W Kelly, A Skibinska, K Esuvaranathan, S Prescott, G D Chisholm, K James.   

Abstract

Intravesical immunotherapy for carcinoma in situ of the bladder is arguably the most effective form of tumour immunotherapy described to date. Following repeated instillations of BCG organisms into the bladder, large quantities of cytokines are detected in patients' urine. This study concerns the production of IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and soluble ICAM-1 (sICAM-1) throughout the six weekly instillations which comprise a therapeutic course. Sequential instillations of BCG induced secretion of IL-1 beta, IL-2, IL-6, IL-8, IL-10, TNF-alpha, IFN-gamma and sICAM-1 into urine. The responses were heterogeneous between patients and cytokines, but some general trends were evident. Although cytokine levels were initially low, their concentration increased with repeated instillation of BCG. Certain cytokines (e.g. IL-6, IL-8 and IL-10) could be detected after the first instillation, whilst others (e.g. IL-2 and IFN-gamma) were not detected until after the third or fourth instillation. Interestingly, IL-4 was not detected, perhaps suggesting a differential effect on Th2-like responses. Some patients produced particularly elevated or non-detectable levels of cytokines, and a positive correlation was found between the production of various cytokines. The production of a particular cytokine did not correspond with lack of production of another species. Whether monitoring the production of cytokines following therapy may be of prognostic value will be determined in a larger series of patients. However, as these potent immunomodulators are thought to be important for the 75% complete clinical response observed with BCG therapy, there remains the possibility that detection of the products of an activated immune system may correlate with eventual clinical outcome. This study is a necessary forerunner to full prognostic evaluation of such immunological data.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882559      PMCID: PMC1534215          DOI: 10.1111/j.1365-2249.1995.tb05560.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

2.  Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.

Authors:  E C Lattime; L G Gomella; P A McCue
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

Review 3.  Carcinoma in situ.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

4.  The inhibitory effects of interferon gamma on the growth of bladder cancer cells.

Authors:  S J Hawkyard; A M Jackson; K James; S Prescott; J F Smyth; G D Chisholm
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

5.  Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

6.  Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration.

Authors:  M Bettex-Galland; U E Studer; A Walz; B Dewald; M Baggiolini
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

7.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James; G D Chisholm
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

9.  Intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience.

Authors:  A P van der Meijden; P A Steerenberg; W H de Jong; F M Debruyne
Journal:  Anticancer Res       Date:  1991 May-Jun       Impact factor: 2.480

10.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more
  43 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

Review 2.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

3.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 4.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

Review 5.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

6.  Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer.

Authors:  K Taniguchi; S Koga; M Nishikido; S Yamashita; T Sakuragi; H Kanetake; Y Saito
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 7.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Authors:  Akhil Muthigi; Arvin K George; Sam J Brancato; Piyush K Agarwal
Journal:  Ther Adv Urol       Date:  2016-02-09

8.  Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils.

Authors:  Mark P Simons; Jill M Moore; Troy J Kemp; Thomas S Griffith
Journal:  Infect Immun       Date:  2006-12-28       Impact factor: 3.441

9.  Study of recombinant human IFN-α-2b bacilli calmette-guerin activated killer cells and against bladder cancer cell in vitro.

Authors:  Xiaodong Fan; Ruifa Han
Journal:  Front Med China       Date:  2007-10

Review 10.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.